SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Ph

Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL Sys

Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Fr

Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP

ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass

SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today

ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst

ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass

Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report

SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent

ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGla

Nanovibronix (NASDAQ: FEED - Get Free Report) and Spyglass Pharma (NASDAQ: SGP - Get Free Report) ar

Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report

HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a

12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Dru

ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlas

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGla

Middle East tensions are wreaking havoc, with traditional safe havens not providing much protection.

Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-r

Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy

Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a O

Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early mo

Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy ratin

Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change

Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating a

Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Com

UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT

Benzinga's Political Roundup

Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)

The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)

Priceline.com Added To The S&P 500, Replacing Schering-Plough

European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug

US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - NOT FOR DISTRIBUTION TO UNITED STATES